Developing targeted RNA therapeutics that unlock immune recognition in solid tumors by inducing neoantigen expression
Strategic Partners & Recognition
Sebastian Biopharma is developing iTAP, a targeted RNAi therapeutic built on our modular antibody-oligonucleotide conjugate platform. By silencing TAP, a key regulator of antigen presentation, iTAP induces shared neoantigen expression across metastatic tumor deposits—transforming invisible tumors into immune-visible targets. It functions as a monotherapy or potentiates checkpoint inhibitors, directly addressing the FDA-recognized challenge of neoantigen deficiency. Scalable, selective, and clinically adaptable, iTAP offers plug-and-play precision across oncology indications.
Therapeutic Differentiation
Antibody-Oligonucleotide Conjugate Platform
Beyond RNA & Oncology
Sebastian Biopharma is built on a strong scientific and institutional foundation, with FDA-aligned development and expanding strategic momentum. Our pipeline is supported by 15+ peer-reviewed publications, exclusive IP licensed from the University of Miami, and validation through the SCBio Drive Accelerator. Initiated experimental operations in January 2025 to accelerate lead candidate selection and optimization. Currently raising $3-5M in seed funding to achieve IND-ready status within 18 months.
Sebastian Biopharma aims to initiate a biomarker-stratified Phase 1/2 basket trial in Q1 2028, focused on TAP-positive, low-TMB tumors across MSS/MMRp colorectal and other resistant indications. Data from this study will guide expansion into combination regimens with immune-modulators, shaping iTAP’s path toward first-in-class positioning as an immunotherapy amplifier.
Featured by the American Committee for Immunology Research (ACIR), this article highlights Sebastian Biopharma’s approach to reprogramming the tumor microenvironment throught TAP silencing. The result: enhanced tumor visibility, potent antitumor effects in both mouse and human preclinical models, and promising synergy with immune checkpoint blockade—without added toxicity.
Sebastian Biopharma’s platform is built more than a decade of rigorous scientific research and validated across preclinical models. Publications related to iTAP, our lead candidate, further support its potential and scientific foundation.
Nature Communications, 2019
Nature , 2010
Cancer Inmunology Research, 2020
Research Features, 2021
Vaccination against neoantigens induced in cross-priming cDC1 in vivo
Sebastian Biopharma is led by a founding team with decades of combined experience in RNA therapeutics, Immuno-Oncology and company-building, bringing scientific vision and operational discipline to every milestone.
Eli Gilboa, PhD
CSO & Founder
Scientific leader in tumor neoantigen & RNA therapeutics. Multiple grant awarded for Sebastian Bio’s pipeline.
Greta Garrido, PhD
CEO & Co-Founder
Biotech executive driving IO drug development & Strategic growth. Led 2 FDA approvals >50M in successful fundraising.
Our journey is backed by more than belief. These figures highlight the progress we’ve made, from lab bench to investor boardrooms, and where we’re going next.
An exclusive University of Miami license secures our competitive edge and freedom to operate.
Founders and early backers have already invested over half a million dollars in this breakthrough platform.
Our science is backed by high-impact publications in leading oncology and immunology journals.
Investment Opportunity
Our lead candidate, iTAP, is built for synergy across RNA therapeutics, ADC innovation, and immunotherapy – driven by a differentiated payload strategy that enhances diverse treatment modalities. We offer high impact partnering opportunities to expand market reach, extend IP protection, and unlock new immunotherapy pathways.
With strong early data, exclusive IP, and scalable design, Sebastian Biopharma presents a clear commercial opportunity for growth and return.
Your investment will fuel:
- Candidate selection and optimization
- IND-enabling studies
- Strategic engagement prep
We’re building strategic partnerships with investors, collaborators and institutions ready to accelerate the future of oncology.
Drop us an email
contact@sebastianbio.com
Address
100 Cumming Center Suite 451-C Beverly MA 01915